Popularity #4,958Earnings are out
Aytu BioPharma (AYTU)
Commercializer of prescription medicines for depression, ADHD, and pediatric conditions.
$2.13
vs last close−0.10 (−4.48%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Sep 2023 | Q2 FY24Dec 2023 | Q3 FY24Mar 2024 | Q4 FY24Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 19 | 14 | 18 | 17 | 16 | 18 | 15 | 14 | 15 | 12 | 16 |
| Cost of revenue | 5 | 4 | 4 | 6 | 5 | 5 | 6 | 5 | 5 | 6 | 6 | 4 |
| Gross profit | 13 | 15 | 10 | 12 | 12 | 11 | 13 | 10 | 9 | 9 | 7 | 12 |
| 14 | 11 | 12 | 16 | 13 | 12 | 10 | 18 | 11 | 11 | 11 | 10 | |
| Research & development | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | 10 | 10 | 11 | 11 | 10 | 9 | 8 | 10 | 11 | 11 | 10 | |
| Selling & marketing | 6 | 5 | 5 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| General & administrative | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 5 | 5 | 5 | 4 |
| Other expenses | 1 | 1 | 1 | 3 | 2 | 2 | 1 | 9 | 0 | 0 | 0 | 0 |
| Operating income | −1 | 3 | −2 | −4 | −1 | −2 | 2 | −8 | −2 | −2 | −4 | −1 |
| −7 | −2 | 0 | 0 | 2 | 2 | 1 | −12 | 3 | −9 | −2 | 0 | |
| Interest expense | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Other non-operating income | 5 | 0 | −1 | 4 | −3 | −3 | −2 | 11 | −4 | 8 | 1 | 0 |
| Income before tax | −7 | 1 | −2 | −4 | 1 | 0 | 4 | −19 | 2 | −11 | −6 | 0 |
| Income tax expense | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −7 | 1 | −2 | −5 | 1 | 1 | 4 | −20 | 2 | −11 | −6 | 0 |
| Discontinued operations | −1 | −1 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −8 | 0 | −3 | −5 | 1 | 1 | 4 | −20 | 2 | −11 | −6 | 0 |
| EPS, basic | −$1.48 | −$0.04 | −$0.52 | −$0.83 | $0.20 | $0.02 | $0.65 | −$2.92 | $0.21 | −$1.05 | −$0.53 | $0.21 |
| EPS, diluted | −$1.48 | −$0.04 | −$0.52 | −$0.83 | $0.16 | −$0.26 | $0.21 | −$2.92 | −$0.08 | −$1.05 | −$0.53 | $0.50 |
| Weighted average shares, basic | 5 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 9 | 10 | 11 | 12 |
| Weighted average shares, diluted | 5 | 6 | 6 | 6 | 9 | 8 | 8 | 7 | 19 | 10 | 11 | 12 |
| EBITDA | −4 | 4 | 1 | −6 | 4 | 3 | 6 | −17 | 3 | −9 | −4 | −1 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | −6 | 3 | −1 | −8 | 2 | 1 | 5 | −19 | 2 | −10 | −5 | 0 |